Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms

Pharmaceutical Development and Technology
Divyakant DesaiPeter Timmins

Abstract

Fixed dose combination (FDC) products are common in the treatment of hypertension, diabetes, human immunodeficiency virus, and tuberculosis. They make it possible to combine two or more drug molecules with different modes of pharmacological actions in a single dosing unit and optimize the treatment. From a patient perspective, they offer convenience, reduced dosing unit burden, and cost savings. From a clinical perspective, aging population in developed countries will need multiple medications to treat age related diseases and co-morbidities. FDC products simplify dosing regimen and enhance patient compliance. As outlined in the article, the number of FDC products has grown over the years and the trend is likely to continue. This review article gives an overview to pharmaceutical scientists about recent trends in the formulation development of the FDC products and provides decision trees to select most optimum formulation development strategy. While some formulation technologies such as multi-layer tablets, multiparticulate systems, active film coating, and hot-melt granulation are discussed in more detail, a few specialized technologies are also introduced briefly to the readers.

References

Apr 1, 1970·Journal of Pharmaceutical Sciences·J T CarstensenS H Rubin
May 14, 1999·Pharmaceutical Science & Technology Today·R GandhiR Panchagnula
Dec 5, 2000·Journal of Controlled Release : Official Journal of the Controlled Release Society·A StreubelR Bodmeier
May 11, 2004·Drug Development and Industrial Pharmacy·R Talukder, R Fassihi
Dec 15, 2004·Drug Development and Industrial Pharmacy·Alessandro GainottiFerdinando Giordano
Jun 23, 2005·International Journal of Pharmaceutics·H KranzT Wagner
Jun 9, 2006·International Journal of Pharmaceutics·Ahmad Mohamad, Andrei Dashevsky
Jun 13, 2006·Journal of Veterinary Medical Education·Richard P Timmins
Aug 22, 2006·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Therese RiisHeiko Kranz
Sep 14, 2007·International Journal of Pharmaceutics·Quan Liu, Reza Fassihi
Mar 8, 2008·Journal of Pharmaceutical and Biomedical Analysis·P Kowalski
Apr 22, 2008·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Nele PoelvoordeJean-Paul Remon
Jul 24, 2008·Pharmaceutical Development and Technology·G A MohammedArvind Kumar Bansal
Oct 2, 2008·Chemical & Pharmaceutical Bulletin·Jayabalan NirmalMuthuraja Nagarajan
Jan 30, 2009·Diabetes, Obesity & Metabolism·C J Bailey, C Day
Mar 5, 2009·Drug Development and Industrial Pharmacy·A CosijnsJ P Remon
Jun 13, 2009·Pharmaceutical Development and Technology·Daniel FichanaFernando Muzzio
Jul 11, 2009·International Journal of Pharmaceutics·Emma L McConnellAbdul W Basit
Nov 26, 2009·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Gabriella BakiKlára Pintye-Hódi
Dec 8, 2009·International Journal of Pharmaceutics·M S Anuar, B J Briscoe
May 19, 2010·Drug and Alcohol Dependence·B VicknasingamM C Chawarski
May 25, 2010·Journal of Controlled Release : Official Journal of the Controlled Release Society·Shajahan AbdulSunil B Jaiswal
Feb 15, 2011·International Journal of Pharmaceutics·Fridrun Podczeck
Feb 18, 2011·The New England Journal of Medicine·Janet WoodcockRachel E Behrman

❮ Previous
Next ❯

Citations

May 18, 2013·International Journal of Pharmaceutics·Masahiro NiwaKatsuhide Terada
Dec 29, 2013·International Journal of Pharmaceutics·Admassu AbebeAlberto M Cuitiño
Jul 15, 2015·Expert Opinion on Drug Delivery·Felipe L LopezMine Orlu Gul
Mar 16, 2016·International Journal of Pharmaceutics·Sara M HanningMine Orlu Gul
Aug 20, 2015·ACS Medicinal Chemistry Letters·Ping LiuScott D Edmondson
Jul 12, 2016·Journal of Pharmaceutical Sciences·David P ElderRené Holm
Jul 13, 2016·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Felipe L LopezCatherine Tuleu
Sep 27, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Edvin BrusačAna Mornar
Jun 20, 2020·Pharmaceutical Research·Raquel Fernández-GarcíaDolores R Serrano
Dec 15, 2019·Pharmaceutics·Suet Li ChewBahijja Tolulope Raimi-Abraham
Jul 24, 2020·Indian Journal of Endocrinology and Metabolism·Mathew John
Apr 10, 2019·Polymers·Giovanny F Acosta-VélezBenjamin M Wu
Jan 18, 2020·Pharmaceutics·Enrica MendittoIsabel F Almeida
Feb 9, 2021·AAPS PharmSciTech·Jamshed HaneefRenu Chadha
Feb 2, 2021·International Journal of Pharmaceutics·Kwadwo Amanor MfoafoHossein Omidian
Dec 15, 2019·International Journal of Pharmaceutics·Annelies SmeetsGuy Van den Mooter
Mar 5, 2021·International Journal of Pharmaceutics·Lixiang ZhaoGareth R Williams
Dec 25, 2019·European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Für Pharmazeutische Verfahrenstechnik E.V·Shao-Yu Chang, Changquan Calvin Sun
Sep 2, 2020·Molecular Pharmaceutics·Mira El SayedChristel A S Bergström

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.